124276-63-7

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 11 carbon atoms, 7 hydrogen atoms, 3 fluorine atoms, and 1 nitrogen atom.

Explanation

The compound has a nitrile group (C≡N), a cyclopropane ring (a three-membered carbon ring), and a trifluoromethylphenyl group (a phenyl group with a trifluoromethyl substituent).

Explanation

Due to its unique structure and reactivity, 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE is used as a starting material or intermediate in the synthesis of various pharmaceuticals, agrochemicals, and materials with specific properties.

Explanation

The presence of a cyclopropane ring and a trifluoromethylphenyl group in the molecule contributes to its unique properties and reactivity, making it valuable in various chemical applications.

Explanation

The compound's reactivity, due to its functional groups and structural features, allows it to be used as a building block in the synthesis of new and complex organic compounds.

Functional Groups

Nitrile derivative, cyclopropane ring, and trifluoromethylphenyl group

Application

Synthesis of pharmaceuticals, agrochemicals, and advanced materials

Potential Applications

Medicinal chemistry and organic synthesis

Structural Features

Unique cyclopropane ring and trifluoromethylphenyl group

Reactivity

Can be used as a building block in organic synthesis

Upstream product

• 107-04-0 1-Bromo-2-chloroethane 
• 3038-47-9 2-(trifluoromethyl)phenylacetonitrile 

Downstream Products

• 886366-06-9 1-[2-(trifluoromethyl)phenyl]cyclopropanecarboxylic acid 
• 1067188-03-7 2-oxo-2-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)ethyl acetate 
• 1067188-02-6 2-chloro-1-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)ethanone 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS

The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

Efficient cyclopropanation of aryl/heteroaryl acetates and acetonitriles with vinyl diphenyl sulfonium triflate

A convenient method was developed for the cyclopropanation of aryl acetates and aryl acetonitrile using vinyl diphenyl sulfonium triflate salt. The newly developed conditions are simple, mild, and compatible with a wide range of functional groups, without the need to apply an inert atmosphere, or alkali bases.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.